Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic ketogenesis is a **metabolic pathway** occurring primarily in the mitochondria of liver cells, where fatty acids and certain ketogenic amino acids are broken down to produce **ketone bodies**—mainly acetoacetate, beta-hydroxybutyrate, and acetone[2][7]. This process is activated when carbohydrates are scarce, such as during fasting, starvation, prolonged exercise, low-carbohydrate diets, or untreated type 1 diabetes[2][5]. The main steps involve β‑oxidation of fatty acids to acetyl-CoA; condensation to acetoacetyl-CoA; conversion by HMG-CoA synthase to HMG-CoA; cleavage by HMG-CoA lyase to form acetoacetate; with further reduction or decarboxylation yielding beta-hydroxybutyrate and acetone[7]. Ketones produced by the liver serve as an alternative energy source for extrahepatic tissues like brain and muscle when glucose availability is limited. The process also helps prevent hepatic injury from excess fat accumulation by diverting carbon away from the TCA cycle into exportable fuel for other organs[1][3]. Impaired hepatic ketogenesis has been linked with increased risk of steatosis and progression toward more severe forms of fatty liver disease such as MASH/MAFLD[4][5]. Hepatic ketogenesis itself is not a single molecular target but rather a pathway involving several enzymes—most notably mitochondrial 3-hydroxy‑3-methylglutaryl–CoA synthase 2 (**HMGCS2**) as the rate-limiting enzyme. Therefore "hepatic ketogenesis" should not be considered a canonical therapeutic target like an individual receptor or enzyme but rather describes a physiological process involving multiple molecular components. Because it refers to a pathway/process rather than an individual molecule/protein/receptor/enzyme/transporter/etc., this entry should be flagged as incorrect for use as a canonical drug target. For structured data purposes on drug targets, consider instead specific enzymes such as "Mitochondrial 3-hydroxy‑3-methylglutaryl–CoA synthase" (HMGCS2)[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic ketogenesis.